Format

Send to

Choose Destination
Cancer Res. 2008 Jun 1;68(11):4039-44. doi: 10.1158/0008-5472.CAN-07-6314.

Laforin confers cancer resistance to energy deprivation-induced apoptosis.

Author information

1
Division of Immunotherapy, Section of General Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA.

Abstract

A long-standing but poorly understood observation in experimental cancer therapy is the heterogeneity in cancer susceptibility to energy deprivation. Here, we show that the hexose kinase inhibitor 2-deoxyglucose (2-dG) preferentially kills cancer cells with defective laforin expression and significantly increases the survival of mice with aggressive lymphoma due to a genetic defect of the laforin-encoding Epm2a gene. Normal cells from Epm2a(-/-) mice also had greatly increased susceptibility to 2-dG. Thus, laforin is a novel regulator for cellular response to energy deprivation and its defects in cancer cells may be targeted for cancer therapy.

PMID:
18519661
PMCID:
PMC2440919
DOI:
10.1158/0008-5472.CAN-07-6314
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center